A kind of crystal form of valbenazine di-p-toluenesulfonate and its preparation method and use

A technology of p-toluenesulfonate and crystal form, applied in the field of medicinal chemistry, can solve the problems of low yield and large loss of raw materials, and achieve the effects of low adhesion, excellent adhesion and improved product appearance

Active Publication Date: 2022-03-29
CRYSTAL PHARMA CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] However, the inventors of the present application have found through research that the acquisition of Form I in the prior art has a large loss of raw materials and a low yield. As described in Example 2 of WO2017075340A1, the yield is only 69%. In addition, it is found through research that Form I There are also problems of solubility, hygroscopicity, and powder science

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of crystal form of valbenazine di-p-toluenesulfonate and its preparation method and use
  • A kind of crystal form of valbenazine di-p-toluenesulfonate and its preparation method and use
  • A kind of crystal form of valbenazine di-p-toluenesulfonate and its preparation method and use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0116] The preparation method of embodiment 1 crystal form CSIII

[0117] Weigh 432.1 mg of free base in a glass vial, add 390.8 mg of p-toluenesulfonic acid, then add 1 mL of 2-MeTHF into the vial, stir at room temperature for 3 minutes, add 1 mL of 2-MeTHF and 200 μL of water, stirred at -20°C, and the solid was separated to obtain the crystal form CSIII. Form CSIII is a co-solvate of 2-MeTHF and water, its XRPD pattern is as follows figure 1 shown.

Embodiment 2

[0118] The preparation method of embodiment 2 crystal form A

[0119] Put 46.2mg of crystal form CSIII in 2.3mL of anisole solvent, suspend and stir at 4°C, and separate the solid. At this time, the obtained solid is crystal form N4, and its XRPD pattern is as follows figure 2 shown. Form N4 was vacuum-dried at room temperature to obtain a white solid. After testing, the obtained crystalline solid is the crystal form A of the present invention, and its X-ray powder diffraction data are shown in Table 1, and its XRPD pattern is as follows image 3 .

[0120] Table 1

[0121] Diffraction angle 2θ d value strength% 5.88 15.03 100.00 7.06 12.52 3.97 8.68 10.18 4.82 10.98 8.05 5.50 13.29 6.66 14.80 14.27 6.21 3.81 15.75 5.63 10.38 16.26 5.45 4.06 16.96 5.23 2.53 18.15 4.89 5.91 19.00 4.67 5.70 19.76 4.49 17.66 21.58 4.12 4.90 22.88 3.89 3.61 26.98 3.30 2.41 29.40 3.04 ...

Embodiment 3

[0122] The preparation method of embodiment 3 crystal form A

[0123] Weigh 500.1mg of free base and 476.1mg of p-toluenesulfonic acid into a 20mL glass vial, add 4.0mL of 2-MeTHF, stir at -20°C for about 1.5h, continue to add 6.0mL of 2-MeTHF, stir After about 1.5 hours, centrifuge, and dry in vacuum at room temperature for about 1.5 hours to obtain a solid.

[0124] Transfer the solid to a 100mL vial, add about 45mL of anisole solvent and stir at -20°C for a period of time, then add about 0.5mL of crystal form N4 seed crystal suspension and continue stirring. After filtering under the condition and vacuum drying at room temperature overnight, 795.8 mg of crystalline form A was obtained (yield after deducting the seed crystal: 84%). Its XRPD pattern is as follows Figure 4 As shown, the XRPD data are shown in Table 2. TGA as Figure 5 As shown, there is about 2.61% mass loss when it is heated to 150°C. DSC such as Figure 6 As shown, it appears an endothermic peak aro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
tensile strengthaaaaaaaaaa
tensile strengthaaaaaaaaaa
Login to view more

Abstract

A crystal form of Valbenazine di-p-toluenesulfonate and its preparation method, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of vesicular monoamine transporter 2 inhibitors and pharmaceutical preparations for treating tardive dyskinesia use in .

Description

technical field [0001] The present invention relates to the field of medicinal chemistry. Specifically, it relates to a crystal form of Valbenazine di-p-toluenesulfonate and a preparation method and use thereof. Background technique [0002] Tardive Dyskinesia (TD) is a neurological condition characterized by involuntary movements of the orofacial region (ie, tongue, lips, jaw, face) and choreoathetoid movements of the extremities and trunk. People with mild TD are often unaware of involuntary movements, so they do not seek treatment. As symptoms increase in severity, hyperkinetic movements begin to disrupt normal speech, chewing, breathing, facial expression, limb movement, walking, and balance. In the most severe cases, TD may result in self-injury, abrasions, lacerations, and difficulty dressing, eating, or drinking. [0003] Dysregulation of the dopaminergic system is part of several CNS disorders, including hyperkinetic movement disorders such as tardive dyskinesia (...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D471/04A61P25/00A61K31/4375
CPCA61K31/4375A61P25/00C07D471/04A61K31/4745C07B2200/13
Inventor 陈敏华张炎锋杨朝惠黄春香
Owner CRYSTAL PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap